BMS202 (PD-1/PD-L1 inhibitor 2), small-molecule inhibitor

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Interferon beta often referred to as IFN-β is a cytokine that plays an essential role in the immune response. It is known for its antiviral antiproliferative and immunomodulatory functions. Interferon beta is produced by fibroblasts and leukocytes and can be found in various tissues including blood. The molecular mass of IFN-β is around 20 kDa. Another name it goes by is BMS-202 a small molecule sometimes involved in modulating its activity by inhibiting interactions with other molecules like PD-L1.

Biological function summary

Interferon beta aids in regulating immune responses and inflammation. It is part of the larger interferon type I family and contributes to the cellular defense mechanism against pathogens. IFN-β interacts with its receptor IFNAR forming a complex that activates various transcription factors and signaling pathways within cells. The activity of IFN-β is important for the modulation of different immune cells including T cells and natural killer cells enhancing the body's ability to fight infections and potentially cancer.

Pathways

Interferon beta is involved in the JAK-STAT signaling pathway which regulates gene expression and cellular responses to extracellular signals. This pathway is closely related to immune system modulation and is significant for the function of PD-L1 with which IFN-β interacts. Interferon beta also plays roles in the MAPK signaling pathway influencing cell growth and apoptosis. Through these pathways IFN-β interacts with various proteins such as STAT1 and STAT2 which are essential in executing its biological effects.

Interferon beta has a connection with multiple sclerosis and certain types of cancer. In multiple sclerosis IFN-β is used therapeutically to reduce the frequency of relapses by modulating immune response and inflammation. It is believed that IFN-β affects the expression of PD-L1 which inhibits T-cell activity hence it may impact tumor growth in some cancers. The relationship between IFN-β and the PD-1/PD-L1 axis is of particular interest in cancer therapy where modulation of these interactions can lead to improved immune response against tumor cells.